What Are Organoids and How They Replace Animal Testing

Mini Organs in a Dish

Somewhere in a laboratory, a cluster of cells no larger than a pencil eraser is doing something remarkable: it is organizing itself into a tiny, functioning replica of a human kidney. This is an organoid—a three-dimensional, miniaturized version of an organ grown from stem cells in a lab dish. Though only a few millimetres across, organoids replicate the architecture, cell diversity, and even some functions of real organs.

Scientists have built organoids mimicking brains, livers, hearts, intestines, stomachs, lungs, kidneys, and pancreases. Each one offers a window into human biology that flat cell cultures and animal models have never been able to provide—and regulators are beginning to take notice.

How Organoids Are Made

Every organoid starts with stem cells, either harvested from adult tissue or reprogrammed from a patient's own skin or blood cells (known as induced pluripotent stem cells, or iPSCs). Researchers embed these cells in a protein-rich gel matrix—often a substance called Matrigel—that mimics the body's extracellular scaffolding.

By adding carefully timed cocktails of signaling molecules, scientists nudge the stem cells to differentiate into specific cell types. The cells then self-organize, spontaneously arranging themselves into structures that echo the tissue they are designed to model. A brain organoid, for example, develops distinct neural layers; a gut organoid forms the finger-like projections called villi found in real intestines.

The entire process can take days to weeks, depending on the organ type and complexity required.

Why They Matter for Drug Discovery

Roughly nine out of ten drug candidates fail in clinical trials, often because results in mice or rats do not translate to humans. Organoids address this gap by providing a human-relevant testing platform. Because they are derived from human cells, they avoid the interspecies variability that plagues animal models.

Drug companies can grow patient-specific organoids to predict how an individual will respond to a treatment—a cornerstone of personalized medicine. In one notable application, researchers grew mini-gut organoids from rectal tissue of cystic fibrosis patients carrying rare mutations to determine whether new therapies would work for them, according to Harvard's Stem Cell Institute.

Pharmaceutical giant Roche has invested heavily in the technology, inaugurating a dedicated Institute of Human Biology in Basel in March 2026 that houses 250 researchers working with organoids and organ-on-chip systems.

The Regulatory Shift Away From Animals

For decades, U.S. law required animal testing before any new drug could enter human trials. That changed with the FDA Modernization Act 2.0, signed in December 2022, which for the first time allowed non-animal alternatives—including organoids—to support new drug applications.

The momentum accelerated. In 2025, the FDA released a roadmap to reduce animal testing, initially targeting monoclonal antibodies. By early 2026, the agency issued draft guidance encouraging developers to adopt New Approach Methodologies (NAMs), including organoids, computational models, and organ-on-chip systems. Congress reinforced the shift with the FDA Modernization Act 3.0, passed unanimously by the Senate in late 2025.

Current Limitations

Organoids are powerful but imperfect. Most lack a blood vessel network, which limits their size and the nutrients that can reach interior cells. They also typically lack immune cells and nervous system connections, meaning they cannot fully replicate how a drug behaves inside a living body.

Reproducibility remains a challenge: two organoids grown from the same cell line can develop differently, making standardized comparisons difficult. The protein matrices used to grow them can vary between batches, introducing further inconsistency.

Recent breakthroughs are closing some of these gaps. In 2025, Stanford researchers reported growing mini hearts, lungs, and livers that developed their own blood vessels—a milestone that could eventually allow organoids to grow larger and function more like real organs.

What Comes Next

Researchers envision linking multiple organoids together—a liver connected to a heart connected to a kidney—to create "body-on-a-chip" systems that simulate how drugs move through the entire body. Combined with artificial intelligence to analyze the results, such platforms could dramatically cut the time and cost of bringing a new medicine to market.

Organoids will not replace all animal testing overnight. But as the science matures and regulatory frameworks evolve, these tiny lab-grown structures are steadily reshaping how humanity develops drugs, studies disease, and understands its own biology.